Lipofen Alternatives Compared
| Lipofen (fenofibrate) | Fenofibrate | Atorvastatin |
|
|---|
| Lipofen (fenofibrate) | Fenofibrate | Atorvastatin |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Hypertriglyceridemia, Hyperlipoproteinemia Type IIa - Elevated LDL, Hyperlipoproteinemia, Hyperlipoproteinemia Type IV - Elevated VLDL, Hyperlipoproteinemia Type IIb - Elevated LDL... View more |
Prescription only
Fenofibrate is effective at reducing triglyceride levels and increasing HDL cholesterol levels; however, it is less effective than statins at reducing LDL cholesterol levels. Fenofibrate tablets... View more |
Prescription only
Atorvastatin is effective at lowering cholesterol; however, its use may be limited by side effects such as muscle pain. Prescribed for High Cholesterol, High Cholesterol - Familial Homozygous, High... View more |
Related suggestions Hyperlipoproteinemia
Hyperlipoproteinemia Type IIa, Elevated LDL
Hyperlipoproteinemia Type IIb, Elevated LDL VLDL
|
|||||||||||||||||||||||
| More about Lipofen (fenofibrate) | More about Fenofibrate | More about Atorvastatin | ||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Lipofen has an average rating of 8.5 out of 10 from a total of 2 ratings on Drugs.com. 50% of reviewers reported a positive effect, while 0% reported a negative effect. |
Fenofibrate has an average rating of 5.7 out of 10 from a total of 71 ratings on Drugs.com. 44% of reviewers reported a positive effect, while 37% reported a negative effect. |
Atorvastatin has an average rating of 4.4 out of 10 from a total of 303 ratings on Drugs.com. 28% of reviewers reported a positive effect, while 53% reported a negative effect. |
||||||||||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||||||||||
|
View all Lipofen side effects |
View all Fenofibrate side effects |
View all Atorvastatin side effects |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Generic Availability | ||||||||||||||||||||||||||
|
Lower cost generic |
Lower cost generic |
|||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Lipofen prices |
View all Fenofibrate prices |
View all Atorvastatin prices |
||||||||||||||||||||||||
| Dosage Forms | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
| Other fenofibrate brands include: Antara, Fenoglide, TriCor, Triglide | Antara, Fenoglide, Lipofen, TriCor, Triglide | Atorvaliq, Lipitor | ||||||||||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||||||||||
|
20 hours |
20 hours |
14 hours |
||||||||||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category X
Not for use in pregnancy
See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 147 drugs are known to interact with Lipofen:
|
A total of 147 drugs are known to interact with Fenofibrate:
|
A total of 406 drugs are known to interact with Atorvastatin:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
January 11, 2006 |
December 31, 1993 |
December 17, 1996 |
||||||||||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient Resources | ||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
|
||||||||||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.